tadalafil has been researched along with transforming growth factor beta in 6 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (transforming growth factor beta) | Trials (transforming growth factor beta) | Recent Studies (post-2010) (transforming growth factor beta) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 49,119 | 560 | 17,610 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kass, DA | 1 |
| Che, JP; Li, W; Liu, M; Liu, YZ; Wang, GC; Yan, Y; Zhai, W; Zheng, JH; Zhu, CY | 1 |
| Abdel-Salam, RM; Ahmed, NA; Mansour, HM; Salama, AAA; Yassen, NN; Zaki, HF | 1 |
| Ayyıldız, A; Ayyıldız, SN; Benli, E; Çetinkol, Y; Cırrık, S; Köktürk, S; Noyan, T | 1 |
| El-Abhar, HS; Mansour, SM; Soubh, AA | 1 |
| Aoki, Y; Inamura, S; Ito, H; Kobayashi, H; Nagase, K; Taga, M; Yokoyama, O; Zha, X | 1 |
1 review(s) available for tadalafil and transforming growth factor beta
| Article | Year |
|---|---|
Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.
Topics: Carbolines; Cardiomyopathy, Dilated; Cyclic AMP; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Fibrosis; Heart; Heart Failure; Humans; Hypertrophy; Myocardium; Phosphodiesterase 5 Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Transforming Growth Factor beta; TRPC Cation Channels; Ventricular Remodeling | 2012 |
5 other study(ies) available for tadalafil and transforming growth factor beta
| Article | Year |
|---|---|
Preventive effect of phosphodiesterase 5 inhibitor tadalafil on experimental post-pyelonephritic renal injury in rats.
Topics: Acute Disease; Animals; Blood Pressure; Carbolines; Cytokines; Escherichia coli Infections; Kidney; Male; Phosphodiesterase 5 Inhibitors; Pyelonephritis; Rats; Rats, Wistar; Tadalafil; Transforming Growth Factor beta | 2014 |
The anti-inflammatory and anti-fibrotic effects of tadalafil in thioacetamide-induced liver fibrosis in rats.
Topics: Actins; Animals; Anti-Inflammatory Agents; Biomarkers; Collagen Type I; Cytokines; Gene Expression; Hydroxyproline; Inflammation; Interleukin-10; Interleukin-1beta; Interleukin-6; Liver; Liver Cirrhosis; Male; Nitric Oxide; Rats; Rats, Wistar; Tadalafil; Thioacetamide; Transaminases; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2018 |
Positive outcomes of phosphodiesterase type 5 inhibitor on histopathologic and biochemical changes induced by ureteral obstruction.
Topics: Actins; Animals; Enzyme-Linked Immunosorbent Assay; Inflammation; Male; Phosphodiesterase 5 Inhibitors; Rats, Sprague-Dawley; Reference Values; Reproducibility of Results; Tadalafil; Transforming Growth Factor beta; Up-Regulation; Ureter; Ureteral Obstruction | 2019 |
MiR-200a inversely correlates with Hedgehog and TGF-β canonical/non-canonical trajectories to orchestrate the anti-fibrotic effect of Tadalafil in a bleomycin-induced pulmonary fibrosis model.
Topics: Animals; Bleomycin; Dexamethasone; Disease Models, Animal; Hedgehog Proteins; Male; MicroRNAs; Phosphodiesterase 5 Inhibitors; Pulmonary Fibrosis; Rats; Rats, Wistar; Tadalafil; Transforming Growth Factor beta | 2021 |
Phosphodiesterase 5 inhibitor suppresses prostate weight increase in type 2 diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insulin-Like Growth Factor I; Male; Phosphodiesterase 5 Inhibitors; Prostate; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Tadalafil; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Weight Gain | 2022 |